
BCAX Stock Forecast & Price Target
BCAX Analyst Ratings
Bulls say
Bicara Therapeutics Inc. is positioned favorably within the biopharmaceutical sector due to its innovative bifunctional therapy, ficerafusp alfa, which exhibits a promising overall response rate (ORR) that significantly outperforms current standard treatments such as Keytruda. The therapy, in combination with Keytruda, has demonstrated a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months, indicating a strong survival benefit compared to existing therapies. Furthermore, clinical data suggests that this combination may provide a more effective treatment option for patients with solid tumors, reinforcing a positive outlook for the company's stock.
Bears say
Bicara Therapeutics Inc. reported a net loss of $0.50 per share for 2Q25, consistent with prior estimates, indicating a challenging financial performance as the company continues to navigate clinical development. Numerous risks were outlined, including the potential for negative clinical results with its primary asset, ficerafusp alfa, and possible delays in advancing this treatment into registrational trials, which could hinder future growth. Additionally, the projected full-year 2025 net loss of $2.27 per share suggests ongoing financial instability and the risk of dilution may further impact investor confidence and stock performance.
This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares